The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2023

Filed:

Nov. 23, 2020
Applicants:

The Johns Hopkins University, Baltimore, MD (US);

Ústav Organické Chemie a Biochemie Av {hacek Over (C)}r, V.v.i., Prague, CZ;

Inventors:

Barbara Slusher, Kingsville, MD (US);

Jonathan Powell, Baltimore, MD (US);

Lukas Tenora, Prague, CZ;

Pavel Majer, Sykesville, MD (US);

Andrej Jancarik, Koprivnice, CZ;

Robert Leone, Lutherville, MD (US);

Judson Englert, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/198 (2006.01); A61K 39/39 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/198 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01);
Abstract

The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R, R, R', and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).


Find Patent Forward Citations

Loading…